Research peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
This page discusses each of the main elements in the mixture of fission products produced by nuclear fission of the common nuclear fuels uranium and plutonium. The isotopes are listed by element, in order by atomic number. Neutron capture by the nuclear fuel in nuclear reactors and atomic bombs also produces actinides and transuranium elements (not listed here). These are found mixed with fission products in spent nuclear fuel and nuclear fallout. Neutron capture by materials of the nuclear reactor (shielding, cladding, etc.) or the environment (seawater, soil, etc.) produces activation products (not listed here). These are found in used nuclear reactors and nuclear fallout. A small but non-negligible proportion of fission events produces not two, but three fission products (not counting neutrons or subatomic particles). This ternary fission usually produces a very light nucleus such as helium (about 80% of ternary fissions produce an alpha particle) or hydrogen (most of the rest produce tritium or to a lesser extent deuterium and protium) as the third product. This is the main source of tritium from light water reactors. Another source of tritium is Helium-6 which immediately decays to (stable) Lithium-6. Lithium-6 produces tritium when hit by neutrons and is one of the main sources of commercially or militarily produced tritium. If the first or only step of nuclear reprocessing is an aqueous solution (as is the case in PUREX) this poses a problem as tritium contamination cannot be removed from water other than by costly isotope separation.
== Adverse effects == The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections . The most serious side effects include ketoacidosis (high blood levels of acids called ‘ketoacids’), pancreatitis (inflammation of the pancreas), hypersensitivity (allergic reactions) and hypoglycaemia (low blood sugar levels).
[...] if the Russian Federation's Ministry of Defense did not publish such data [indicating the timeline of Russian military activities], then the suspicion grows elsewhere that perhaps they are covering something up such as the exact times they moved." Thomas contended that it was "likely" Saakashvili did not intend to use force "until he was cornered by events." Thomas stated that analysts saw the Russian activities in Abkhazia before August 2008 "as a deception operation to draw attention away from preparations underway in South Ossetia." Thomas criticized the Russian research The Tanks of August because it "omitted crucial meetings and attempts of Georgia to avoid conflict and none of the events were documented with footnotes." Thomas noted, "Russia refused to negotiate with Georgia in the crucial days before conflict erupted. [...] Artillery duels were heavier than in the past, and some artillery positions were located behind Russian peacekeeping forces in South Ossetia." Thomas further stated, "The conclusion that many analysts have reached is that the actions of the Russians were preplanned and that they drew the Georgians into a decision dilemma: either act or lose territory. [...] One of the problems with the Russian version of events is that it ignores all of the positive things Georgia did to prevent fighting from ever breaking out." In 2012, Rick Fawn and Robert Nalbandov wrote that "the precise timing of events on the night of 7–8 August 2008 is a substantial study in itself, and depends on all of the inputs being provable.
Sources: en.wikipedia.org
== External links == Elastin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Histology image: 21402loa – Histology Learning System at Boston University GeneReviews/NIH/NCBI/UW entry on Williams or Williams-Beuren Syndrome The Elastin Protein Microfibril This article incorporates text from the United States National Library of Medicine, which is in the public domain.
The historicity of the United Monarchy is heavily debated among archaeologists and biblical scholars: biblical maximalists and centrists (Kenneth Kitchen, William G. Dever, Amihai Mazar, Baruch Halpern and others) argue that the biblical account is more or less accurate, while biblical minimalists (Israel Finkelstein, Ze'ev Herzog, Thomas L. Thompson and others) argue that Israel and Judah never split from a singular state. The debate has not been resolved, but recent archaeological discoveries by Eilat Mazar and Yosef Garfinkel show some support for the existence of the United Monarchy. From 850 BCE onwards, a series of inscriptions mention the "House of David". They came from Israel's neighbours.
=== Ulcerative colitis === Infliximab targets TNF, thought to be more related to Th1 cytokines. Ulcerative colitis was thought to be a Th2 disease, and infliximab would be of limited use. However, patients with ulcerative colitis have begun to be treated with infliximab on the basis of two large clinical trials conducted in 2005 by Paul Rutgeerts and William Sandborn. The Acute ulcerative Colitis Treatment trials (ACT1 and ACT2) to evaluate the utility of infliximab in ulcerative colitis showed 44–45% of patients treated with infliximab for a year maintained a response to the medication, compared with 21% of patients who were treated with placebo medication. At two months, the response was 61–69% for patients treated with infliximab, and 31% for those treated with placebo.
Sources: en.wikipedia.org
== The war years == What was meant to be a short stay in the US turned into a much longer one as a result of World War II. Switzerland, ringed by hostile forces, advised Hofmann, an officer in the Swiss militia, not to return for the course of the war. He spent the war years working as a guest at Ciba Pharmaceutical Company in New Jersey. From there he moved to the University of Pittsburgh at a time when the institution was trying to build a research reputation.
== Function == Lumican is a major keratan sulfate proteoglycan of the cornea but is ubiquitously distributed in most mesenchymal tissues throughout the body. Lumican is involved in collagen fibril organization and circumferential growth, corneal transparency, and epithelial cell migration and tissue repair. Corneal transparency is possible due to the exact alignment of collagen fibers by lumican (and keratocan) in the intrafibrillar space.
=== External phylogeny === Animals are monophyletic, meaning they are derived from a common ancestor. Animals are the sister group to the choanoflagellates, with which they form the Choanozoa. Ros-Rocher and colleagues (2021) trace the origins of animals to unicellular ancestors, providing the external phylogeny shown in the cladogram. Uncertainty of relationships is indicated with dashed lines. The animal clade had certainly originated by 650 mya, and may have come into being as much as 800 mya, based on molecular clock evidence for different phyla.
Naturally occurring lutetium (71Lu) is composed of one stable isotope 175Lu (97.40% natural abundance) and one long-lived radioisotope, 176Lu with a half-life of 37 billion years (2.60% natural abundance). Forty synthetic radioisotopes have been added from 149Lu to 190Lu, with the most stable being 174Lu with a half-life of 3.31 years and 173Lu with a half-life of 1.37 years. All of the remaining radioactive isotopes have half-lives that are less than 9 days, and the majority of these have half-lives that are less than half an hour. Of the meta states known for this element, the most stable are 177m3Lu (t1/2 160.4 days) and 174mLu (t1/2 142 days). The primary decay mode before the most abundant stable isotope, 175Lu, is electron capture (with some alpha and positron emission), leading to ytterbium or less often thulium isotopes, and the primary mode after is beta emission giving hafnium isotopes. All isotopes of lutetium are either radioactive or, for the lone stable isotope 175Lu, observationally stable, meaning that it is predicted to be radioactive (to alpha decay) but no decay has been observed.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Liquid chromatography–mass spectrometry is commonly used. It provides molecular mass and purity information. Other methods may include HPLC with ultraviolet detection.